Accumulating evidence has implicated immune dysfunction, and in particular hyperactivity of NF-kB signalling, in the pathogenesis of HD, suggesting that interventions targeting this pathway may be of therapeutic value. This evidence concerns the gene NFKB1 and immune system disorder.